FDA Accepts Eisai’s Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBITM (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
TOKYO and CAMBRIDGE, Mass., Mar 6, 2023 – (JCN Newswire) – Eisai Co., Ltd. and…